Lithuanian startup Biomatter raises $18 million in an oversubscribed Series A round to scale its AI enzyme design platform. The funding is led by Astanor, with existing investors including UVC Partners, Inventure, and Metaplanet also participating. The company says the round supports faster development of custom enzymes, and it announces the fundraising via a press release distributed by Business Wire on 12 November; no valuation is disclosed.

Both outlets frame the announcement around the same core elements: the amount raised, the Series A structure, the lead investor, and the involvement of prior backers. Tech.eu emphasizes speeding up enzyme development with AI, while The Next Web highlights the goal of scaling its AI enzyme design platform and the company’s base in Vilnius. Neither source provides additional technical details beyond the focus on AI-driven enzyme design.